TY - JOUR
T1 - Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma
AU - Phillips, Tycel
AU - Chan, Henry
AU - Tam, Constantine S.
AU - Tedeschi, Alessandra
AU - Johnston, Patrick
AU - Oh, Sung Yong
AU - Opat, Stephen
AU - Eom, Hyeon Seok
AU - Allewelt, Heather
AU - Stern, Jennifer C.
AU - Tan, Ziwen
AU - Novotny, William
AU - Huang, Jane
AU - Trotman, Judith
N1 - Publisher Copyright:
© 2022 by The American Society of Hematology.
PY - 2022/6/14
Y1 - 2022/6/14
N2 - Outcomes for marginal zone lymphoma (MZL) and follicular lymphoma (FL) remain suboptimal, owing to the limited number of approved agents and the incurable nature of the diseases. BGB-3111-AU-003 was a phase 1/2, open-label, multicenter, single-agent study of the selective Bruton’s tyrosine kinase inhibitor zanubrutinib in 385 patients with B-cell malignancies. Here, we present safety and efficacy outcomes for the 53 enrolled patients with relapsed/refractory MZL (n 5 20) and relapsed/refractory FL (n 5 33), all of whom were enrolled during the part 2 dose expansion, and therefore received zanubrutinib at the recommended phase 2 dose. Treatment with zanubrutinib was generally well tolerated, with most adverse events being # grade 2. Atrial fibrillation/flutter was not reported. Two patients required dose reduction, and 4 patients discontinued treatment because of adverse events. Response was assessed by an independent review committee for MZL and the investigators for FL, per Lugano 2014 classification for non-Hodgkin lymphoma. In patients with MZL, the overall response rate (ORR) was 80%, and the complete response (CR) rate was 20%. With median follow-up of 33.8 months, median progression-free survival (PFS) was not reached. In patients with FL, the ORR was 36.4%, and the CR rate was 18.2%. After a median follow-up of 33.9 months, median PFS was 10.4 months. In conclusion, the results of this study suggest a favorable benefit–risk profile and support zanubrutinib as a potentially meaningful addition to available therapies for patients with relapsed/refractory MZL and FL. This trial was registered at www.clinicaltrials.gov as #NCT02343120.
AB - Outcomes for marginal zone lymphoma (MZL) and follicular lymphoma (FL) remain suboptimal, owing to the limited number of approved agents and the incurable nature of the diseases. BGB-3111-AU-003 was a phase 1/2, open-label, multicenter, single-agent study of the selective Bruton’s tyrosine kinase inhibitor zanubrutinib in 385 patients with B-cell malignancies. Here, we present safety and efficacy outcomes for the 53 enrolled patients with relapsed/refractory MZL (n 5 20) and relapsed/refractory FL (n 5 33), all of whom were enrolled during the part 2 dose expansion, and therefore received zanubrutinib at the recommended phase 2 dose. Treatment with zanubrutinib was generally well tolerated, with most adverse events being # grade 2. Atrial fibrillation/flutter was not reported. Two patients required dose reduction, and 4 patients discontinued treatment because of adverse events. Response was assessed by an independent review committee for MZL and the investigators for FL, per Lugano 2014 classification for non-Hodgkin lymphoma. In patients with MZL, the overall response rate (ORR) was 80%, and the complete response (CR) rate was 20%. With median follow-up of 33.8 months, median progression-free survival (PFS) was not reached. In patients with FL, the ORR was 36.4%, and the CR rate was 18.2%. After a median follow-up of 33.9 months, median PFS was 10.4 months. In conclusion, the results of this study suggest a favorable benefit–risk profile and support zanubrutinib as a potentially meaningful addition to available therapies for patients with relapsed/refractory MZL and FL. This trial was registered at www.clinicaltrials.gov as #NCT02343120.
UR - http://www.scopus.com/inward/record.url?scp=85132826825&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85132826825&partnerID=8YFLogxK
U2 - 10.1182/bloodadvances.2021006083
DO - 10.1182/bloodadvances.2021006083
M3 - Article
C2 - 35390135
AN - SCOPUS:85132826825
SN - 2473-9529
VL - 6
SP - 3472
EP - 3479
JO - Blood Advances
JF - Blood Advances
IS - 11
ER -